Resistance mechanisms in clinical isolates of Candida albicans

被引:361
|
作者
White, TC
Holleman, S
Dy, F
Mirels, LF
Stevens, DA
机构
[1] Seattle Biomed Res Inst, Seattle, WA 98109 USA
[2] Univ Washington, Dept Pathobiol, Sch Publ Hlth & Community Med, Seattle, WA 98195 USA
[3] Santa Clara Valley Med Ctr, Dept Med, San Jose, CA USA
[4] Calif Inst Med Res, San Jose, CA USA
[5] Stanford Univ, Stanford, CA 94305 USA
关键词
D O I
10.1128/AAC.46.6.1704-1713.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Resistance to azole antifungals continues to be a significant problem in the common fungal pathogen Candida albicans. Many of the molecular mechanisms of resistance have been defined with matched sets of susceptible and resistant clinical isolates from the same strain. Mechanisms that have been identified include alterations in the gene encoding the target enzyme ERG11 or overexpression of efflux pump genes including CDR1, CDR2, and MDR1. In the present study, a collection of unmatched clinical isolates of C albicans was analyzed for the known molecular mechanisms of resistance by standard methods. The collection was assembled so that approximately half of the isolates were resistant to azole drugs. Extensive cross-resistance was observed for fluconazole, clotrimazole, itraconazole, and ketoconazole. Northern blotting analyses indicated that overexpression of CDR1 and CDR2 correlates with resistance, suggesting that the two genes may be coregulated. MDR1 overexpression was observed infrequently in some resistant isolates. Overexpression of FLU1, an efflux pump gene related to MDR1, did not correlate with resistance, nor did overexpression of ERG11. Limited analysis of the ERG11 gene sequence identified several point mutations in resistant isolates; these mutations have been described previously. Two of the most common point mutations in ERG11 associated with resistance, D116E and E266D, were tested by restriction fragment length polymorphism analysis of the isolates from this collection. The results indicated that the two mutations occur frequently in different isolates of C. albicans and are not reliably associated with resistance. These analyses emphasize the diversity of mechanisms that result in a phenotype of azole resistance. They suggest that the resistance mechanisms identified in matched sets of susceptible and resistant isolates are not sufficient to explain resistance in a collection of unmatched clinical isolates and that additional mechanisms have yet to be discovered.
引用
收藏
页码:1704 / 1713
页数:10
相关论文
共 50 条
  • [1] Molecular Mechanisms of Azole Resistance in Four Clinical Candida albicans Isolates
    Shi, Hongzhuo
    Zhang, Yanli
    Zhang, Ming
    Chang, Wenqiang
    Lou, Hongxiang
    MICROBIAL DRUG RESISTANCE, 2021, 27 (12) : 1641 - 1651
  • [2] Characterization of azole resistance mechanisms in Chilean clinical isolates of Candida albicans
    Fuentes, Marisol
    Hermosilla, German
    Alburquenque, Claudio
    Falconer, Maly A.
    Amaro, Jose
    Tapia, Cecilia
    REVISTA CHILENA DE INFECTOLOGIA, 2014, 31 (05): : 511 - 517
  • [3] Mechanisms of azole resistance in Candida albicans clinical isolates from Shanghai, China
    Liu, Jin-Yan
    Shi, Ce
    Wang, Ying
    Li, Wen-Jing
    Zhao, Yue
    Xiang, Ming-Jie
    RESEARCH IN MICROBIOLOGY, 2015, 166 (03) : 153 - 161
  • [4] The evolution of drug resistance in clinical isolates of Candida albicans
    Ford, Christopher B.
    Funt, Jason M.
    Abbey, Darren
    Issi, Luca
    Guiducci, Candace
    Martinez, Diego A.
    Delorey, Toni
    Li, Bi Yu
    White, Theodore C.
    Cuomo, Christina
    Rao, Reeta P.
    Berman, Judith
    Thompson, Dawn A.
    Regev, Aviv
    ELIFE, 2015, 4 : 1 - 27
  • [5] Molecular mechanisms associated with Fluconazole resistance in clinical Candida albicans isolates from India
    Mane, Arati
    Vidhate, Pallavi
    Kusro, Chanchal
    Waman, Vaishali
    Saxena, Vandana
    Kulkarni-Kale, Urmila
    Risbud, Arun
    MYCOSES, 2016, 59 (02) : 93 - 100
  • [6] Proteomic analysis of azole resistance in Candida albicans clinical isolates
    Hooshdaran, MZ
    Barker, KS
    Hilliard, GM
    Kusch, H
    Morschhäuser, J
    Rogers, PD
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (07) : 2733 - 2735
  • [7] Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates
    Coste, Alix
    Selmecki, Anna
    Forche, Anja
    Diogo, Dorothee
    Bougnoux, Marie-Elisabeth
    d'Enfert, Christophe
    Berman, Judith
    Sanglard, Dominique
    EUKARYOTIC CELL, 2007, 6 (10) : 1889 - 1904
  • [8] Characterization of caspofungin susceptibilities by broth and agar in Candida albicans clinical isolates with characterized mechanisms of azole resistance
    Silver, Peter M.
    Oliver, Brian G.
    White, Theodore C.
    MEDICAL MYCOLOGY, 2008, 46 (03) : 231 - 239
  • [9] Fluconazole resistance is not associated with higher virulence in Candida albicans clinical isolates
    Schulz, B.
    Schmidt, A.
    Borg-von Zepelin, M.
    Ruhnke, M.
    MYCOSES, 2007, 50 (05) : 339 - 340
  • [10] Vulvovaginal Candida albicans Clinical Isolates' Resistance to Phagocytosis In-Vitro
    Faria-Goncalves, Paula
    Oliveira, Ana Sofia
    Gaspar, Carlos
    Rodrigues, Lisa
    Palmeira-de-Oliveira, Rita
    Martinez-de-Oliveira, Jose
    Goncalves, Teresa
    Palmeira-de-Oliveira, Ana
    Rolo, Joana
    LIFE-BASEL, 2022, 12 (06):